Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-09-28Clinical Trial Update: A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification [Phase 3]
Phase 3 trial comparing once-daily insulin degludec / aspart vs insulin glargine + aspart in adults with type 2 diabetes requiring intensifi…
-
CLINICAL_TRIALS trial_result · 2018-09-27Clinical Trial Update: Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema [Phase 4]
Phase 4 trial update assessing empagliflozin for reducing progression of diabetic retinopathy in high-risk patients with diabetic macular ed…
-
FDA approval · 2018-09-26FDA Approved: HUMALOG MIX75/25 — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Humalog Mix75/25 (insulin lispro) filed by Eli Lilly and Company. The action supplements the…
-
FDA approval · 2018-09-26FDA Approved: HUMALOG MIX50/50 KWIKPEN — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Humalog Mix50/50 KwikPen (insulin lispro) from Eli Lilly and Company.
-
FDA approval · 2018-09-24FDA Approved: METFORMIN HYDROCHLORIDE — Original Application (Epic Pharma, LLC)
FDA approved Epic Pharma, LLC's original application for metformin hydrochloride (generic metformin hydrochloride).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-09-21FDA Approved: TRULICITY — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Trulicity (dulaglutide) submitted by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2018-09-18Clinical Trial Update: A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin [Phase 3]
A 24-week open-label phase 3b trial with a 28-week extension evaluated saxagliptin co-administered with dapagliflozin versus insulin glargin…
-
CLINICAL_TRIALS trial_result · 2018-09-18Clinical Trial Update: The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes [Phase 4]
Phase 4 trial updating results on vildagliptin-based treatment versus sulfonylurea for glycemic variability, oxidative stress, GLP-1, and en…
-
CLINICAL_TRIALS trial_result · 2018-09-18Clinical Trial Update: Efficacy and Safety of Nutraceuticals in Patients With Diabetes Mellitus Type II and Dyslipidemia. [Phase 2]
Phase 2 clinical trial evaluating efficacy and safety of nutraceuticals in patients with type 2 diabetes mellitus and dyslipidemia; study co…
-
CLINICAL_TRIALS trial_result · 2018-09-14Clinical Trial Update: Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist [Phase 4]
Phase 4 trial comparing Toujeo with Tresiba in insulin-naive patients with type 2 diabetes inadequately controlled on oral medications ± GLP…
-
CLINICAL_TRIALS trial_result · 2018-09-14Clinical Trial Update: Morbidity in Newly Diagnosed type2 Diabetes in Adults
Completed clinical trial update examining morbidity in adults newly diagnosed with Type 2 Diabetes Mellitus; results were posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-09-13Clinical Trial Update: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes [Phase 3]
Phase 3 trial comparing safety and efficacy of semaglutide once weekly versus sitagliptin once daily in Japanese adults with type 2 diabetes…
-
CLINICAL_TRIALS research · 2018-09-13Clinical Trial Update: Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management [NA]
A completed clinical trial evaluating continuous glucose monitoring to guide glucose management in individuals with chronic kidney disease a…
-
CLINICAL_TRIALS trial_result · 2018-09-12Clinical Trial Update: A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide [Phase 2]
Phase 2 randomized trial comparing semaglutide to placebo and liraglutide in type 2 diabetes; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-09-11Clinical Trial Update: Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan [Phase 3]
Phase 3 trial comparing insulin degludec/insulin aspart twice daily versus biphasic insulin aspart twice daily in adults with type 2 diabete…
-
CLINICAL_TRIALS trial_result · 2018-09-11Clinical Trial Update: Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide [Phase 4]
Phase 4 clinical trial comparing dapagliflozin to gliclazide for effects on vascular function in type 2 diabetes patients, completed.
-
CLINICAL_TRIALS trial_result · 2018-09-11Clinical Trial Update: Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes [Phase 2]
Phase 2 trial evaluating KBP-042 for efficacy and safety in adults with type 2 diabetes has completed.
-
CLINICAL_TRIALS trial_result · 2018-09-11Clinical Trial Update: Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes [NA]
A completed clinical trial study investigating how endothelial function relates to exercise impairment in individuals with type 2 diabetes; …
-
CLINICAL_TRIALS trial_result · 2018-09-10Clinical Trial Update: A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). [Phase 3]
Phase 3 trial evaluating ertugliflozin added to metformin in adults with type 2 diabetes and inadequate glycemic control; results posted aft…
-
CLINICAL_TRIALS trial_result · 2018-09-10Clinical Trial Update: Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes [Phase 4]
Phase 4 clinical trial exploring how dapagliflozin affects urinary proteomic patterns in patients with type 2 diabetes and diabetic nephropa…
-
CLINICAL_TRIALS trial_result · 2018-09-06Clinical Trial Update: Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus [Phase 3]
Phase 3 trial assessing linagliptin added to empagliflozin in Japanese patients with type 2 diabetes; study completed with results posted in…
-
CLINICAL_TRIALS trial_result · 2018-09-06Clinical Trial Update: An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes [Phase 3]
Phase 3 clinical trial investigating the effect of Vitamin D on urine protein levels in adults with type 2 diabetes and diabetic nephropathy…
-
CLINICAL_TRIALS trial_result · 2018-09-06Clinical Trial Update: The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine [Phase 4]
A Phase 4 clinical trial exploring optimal treatment strategies for patients with type 2 diabetes inadequately controlled with glargine.
-
FDA approval · 2018-09-05FDA Approved: BASAGLAR KWIKPEN — Supplemental Application (Eli Lilly and Company)
FDA supplemental application approval for BASAGLAR KWIKPEN (insulin glargine) filed by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2018-09-05Clinical Trial Update: Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes [Phase 3]
Phase 3 trial update for inhaled insulin (AERx iDMS) in type 2 diabetes; the study status is terminated.